Drug agency Zydus Cadila on Friday mentioned it has signed a non-exclusive licensing settlement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a possible remedy for COVID-19.
Remdesivir, the investigational drug from Gilead Sciences Inc, has been issued an ’emergency use authorisation’ (EUA) by the United States Food and Drug Administration (USFDA) to deal with sufferers affected by extreme signs of coronavirus, Zydus Cadila mentioned in an announcement.
Earlier, in May, three home pharmaceutical companies Cipla, Jubilant Life Sciences and Hetero entered into non-exclusive licensing agreements with Gilead Sciences Inc for manufacturing and distribution of remdesivir.
Zydus Chairman Pankaj Patel mentioned, “We are happy to collaborate with Gilead Sciences and increase the access to this life-saving drug for patients suffering from COVID-19.”
In the final decade, Zydus Cadila has been partnering with Gilead Sciences to deal with numerous public healthcare challenges and enhance international entry to reasonably priced need-based therapies, he added.
“At this critical juncture, we join hands once again to ensure that no efforts are spared in the fight against this pandemic,” Patel mentioned.
As a part of the non-exclusive settlement, Zydus will obtain the manufacturing know-how from Gilead Sciences Inc to fabricate the API for remdesivir and the completed product and promote it in 127 nations, together with India, the assertion mentioned.
“Under the agreement, the licence is royalty free until another pharmaceutical product or vaccine is approved for the treatment or prevention of COVID-19 by the USFDA or EMA (European Medicines Agency) or the WHO (World Health Organization) announcing the end of the public health emergency,” it added.
The firm will leverage its potential to scale up manufacturing to achieve sufferers throughout India and in 127 nations in Gilead’s international affected person answer area, the assertion mentioned.
In-vitro testing performed by Gilead has demonstrated that remdesivir is lively in opposition to the virus that causes COVID-19. The security and efficacy of remdesivir to deal with COVID-19 are being evaluated in a number of ongoing Phase-Three scientific trials, it added.
WATCH | Sambit Patra targets Delhi govt over COVID-19 testing